Literature DB >> 16377565

In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets.

Weiguo Zhai1, Hyunkyung Jeong, Libin Cui, Dimitri Krainc, Robert Tjian.   

Abstract

Transcriptional dysregulation has emerged as a potentially important pathogenic mechanism in Huntington's disease, a neurodegenerative disorder associated with polyglutamine expansion in the huntingtin (htt) protein. Here, we report the development of a biochemically defined in vitro transcription assay that is responsive to mutant htt. We demonstrate that both gene-specific activator protein Sp1 and selective components of the core transcription apparatus, including TFIID and TFIIF, are direct targets inhibited by mutant htt in a polyglutamine-dependent manner. The RAP30 subunit of TFIIF specifically interacts with mutant htt both in vitro and in vivo to interfere with formation of the RAP30-RAP74 native complex. Importantly, overexpression of RAP30 in cultured primary striatal cells protects neurons from mutant htt-induced cellular toxicity and alleviates the transcriptional inhibition of the dopamine D2 receptor gene by mutant htt. Our results suggest a mutant htt-directed repression mechanism involving multiple specific components of the basal transcription apparatus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16377565     DOI: 10.1016/j.cell.2005.10.030

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  69 in total

1.  Transcriptional control of amino acid homeostasis is disrupted in Huntington's disease.

Authors:  Juan I Sbodio; Solomon H Snyder; Bindu D Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-19       Impact factor: 11.205

2.  Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Authors:  Haiqun Jia; Judit Pallos; Vincent Jacques; Alice Lau; Bin Tang; Andrew Cooper; Adeela Syed; Judith Purcell; Yi Chen; Shefali Sharma; Gavin R Sangrey; Shayna B Darnell; Heather Plasterer; Ghazaleh Sadri-Vakili; Joel M Gottesfeld; Leslie M Thompson; James R Rusche; J Lawrence Marsh; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2012-05       Impact factor: 5.996

Review 3.  Huntington's Disease and Mitochondria.

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi
Journal:  Neurotox Res       Date:  2017-06-21       Impact factor: 3.911

4.  Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models.

Authors:  Melissa J Leyva; Francesco Degiacomo; Linda S Kaltenbach; Jennifer Holcomb; Ningzhe Zhang; Juliette Gafni; Hyunsun Park; Donald C Lo; Guy S Salvesen; Lisa M Ellerby; Jonathan A Ellman
Journal:  Chem Biol       Date:  2010-11-24

5.  PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Nathalie Launay; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Noel Y Calingasan; Davide Tampellini; Aurora Pujol; M Flint Beal
Journal:  FASEB J       Date:  2014-01-07       Impact factor: 5.191

6.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Authors:  Paula A Desplats; James R Lambert; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2008-05-22       Impact factor: 5.996

7.  Subnuclear segregation of genes and core promoter factors in myogenesis.

Authors:  Jie Yao; Richard D Fetter; Ping Hu; Eric Betzig; Robert Tjian
Journal:  Genes Dev       Date:  2011-02-28       Impact factor: 11.361

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

10.  The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Paula A Desplats; Bin Tang; Elisabetta Soragni; Ryan Burnett; Fuying Gao; Kelsey M Fitzgerald; Jenna F Borok; David Herman; Daniel H Geschwind; Joel M Gottesfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.